Failure of physicians to adhere to hypertension guidelines may partly account for the failure to achieve blood pressure (BP) goals in clinical practice. The aim of this trial is a comprehensive description of the approach of physicians in the management of high BP among primary care patients. It will primarily assess what are the Reasons for not Intensifying an Antihypertensive Treatment (RIAT), when predefined individual BP goals are not achieved. Open intervention survey was conducted in 17 countries in Latin America, Eastern Europe, Africa and Asia in family practices, government and private clinics. The registry is based on a three-step epidemiological design.
Introduction
The risk of cardiovascular diseases (CVD) increases continuously as blood pressure (BP) rises from levels that are considered to be within the normal range. The decision to start treatment, however, depends not only on the level of blood pressure, but also on an assessment of total cardiovascular risk and the presence or absence of target organ damage. In patients with established CVD the choice of antihypertensive drugs depends on the underlying cardiovascular disease. 1 Not surprisingly, therefore, improved recognition, diagnosis and treatment of hypertension rank among the top priorities in all healthcare systems. Several international and national guidelines. [2] [3] [4] [5] have proposed target BP figures to achieve for the management of arterial hypertension according to the presence of associated risk factors or concomitant CVD. Despite these recommendations and the increased knowledge of deleterious consequences of hypertension there is still a substantial proportion of individuals in the general population with hypertension who remain unrecognised, with less than a quarter of the treated patients who have their BP controlled. 2, 6 The most frequent reasons for these disappointing results are on one side the relative inefficacy of the antihypertensive treatments frequently requiring combination therapy in patients with moderate-to-severe hypertension, and on the other side the poor tolerability or the poor compliance leading to an early treatment discontinuation. 7, 8 An under-recognised problem is the failure of consensus guidelines to acknowledge the important difference between efficacy in clinical trials and effectiveness in clinical practice and the fact that clinicians have not fully accepted the current JNC guidelines recommendation of the treatment of stage 1 systolic hypertension or treating to achieve a goal systolic BPo140 mmHg. 9, 10 In the United States, many physicians have been reported to apply BP thresholds for the diagnosis and treatment of hypertension 9 higher than the 140/ 90 mmHg criterion recommended by the JNC. 2 For middle-aged patients with uncomplicated hypertension, 1/3 of physicians would not start drug therapy unless the BP was greater than 95 mmHg diastolic or 160 mmHg systolic. 9 In our previous RIAT survey, we found that there were three main reasons for not intensifying antihypertensive drugs, one of which was the perception of doctors regarding the time to achieve a full effect. 11 There has been little recent research on physician beliefs and practices with regard to the treatment of hypertension, and findings from studies published from 2000 onwards are summarised in Table 1. 9,11-17 
Hospital-based units
Hypertension guidelines in primary care P Ferrari et al Interestingly, current international hypertension guidelines are largely based on information from epidemiological data or intervention trials, which is primarily based on patients from so-called industrialised countries, are of Caucasians and to a smaller degree African Americans background. 4, 5 Very little is known about prevalence, awareness, treatment and response to intervention in Nonwestern countries. Moreover, while the majority of surveys have addressed the prevalence and control of hypertension in the general population, there is a remarkable lack of comprehensive data from large studies on the prevalence of hypertension, its recognition and control in primary care practice. 11, 18, 19 Efforts to improve recognition and management of hypertension 20 are likely to profit substantially from data that provide a fuller understanding of the characteristics of the patient, the doctors and the system that contribute to unsatisfactory levels of recognition and control of hypertension. The lack of such data from these countries prompted us to initiate an international large-scale observational study to assess the characteristics, comorbidities and management issues in patients with hypertension in primary care in countries outside Australia, Canada, Europe, Japan and the United States. This survey will be conducted under the heading 'Reasons for not Intensifying Antihypertensive Treatment' with the acronym RIAT, because one of the key questions addressed is to assess why antihypertensive treatment is not intensified when individual targets are not achieved. Results from a previous survey with a similar design performed in a single country in Europe have been published elsewhere.
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In this article, we present the background, design and methods of the RIAT registry conducted in four continents. Future reports will present more detailed analysis of predictors of poor recognition and control of hypertensive patients in primary care, taking into account the patients' personal and clinical characteristics (attitudes towards treatment, severity, comorbidity). They will also analyse physicians' characteristics and attitudes towards the treatment and management of hypertension, focusing on high-risk constellations, such as patients with hypertension, diabetes and associated illnesses.
Methods
Study design RIAT is a cross-sectional study of unselected patients attending primary care settings, recruited from a representative sample of medical practitioners in 17 countries in Latin America, Eastern Europe, Africa and Asia (Table 2) . In each country a Local National Coordinator, usually a specialist physician with University appointment will supervise the study. The RIAT Program is based on a three-step epidemiological design.
In step one, we will aim at identifying the guidelines and recommendations taken as reference in each country for the management and therapeutic targets for hypertensive patients. This step will assess the practice of medical practitioners only; no data collection on patients will be obtained.
In step two, we will conduct a survey to assess the variance between individual targets defined by medical practitioners compared to national (or international) guidelines and recommendations, in their practice and to identify reasons for such variance when present. Comprehensive data on other cardiovascular risk factors, target organ damage and associated clinical conditions related to hypertension will be collected.
Step three is a prospective registry where physicians will collect patient data at baseline as outlined in step two; determine individual BP values as the target to reach for the next visits and initiate or optimise antihypertensive treatment. Several follow-up visits are proposed to monitor the achievement of these target values. The number of visits and the registry follow-up duration (between 3 and 6 months) will be decided by the investigator according to the local clinical practice and shall be applicable to all physicians for this given country. The physician will have the entire choice of the antihypertensive drug regimen at each visit. The monitors will not suggest any specific drugs to improve the treatment of hypertension.
Step three of RIAT aims at providing responses to four key (2) to assess which percentage of patient really reached the predefined target figures. It has been considered that about 33 000 patients will be included into step three.
Ethical approval and consent
Informed consent will be obtained from all patients. A standardised subject informed consent was prepared by the steering committee and submitted to local ethics committees for approval and, if necessary, amendments to comply with local policies.
Sampling of medical practitioners
The study shall be based on a representative nation wide sample of doctors with primary care functions (general practitioners, specialists in internal medicine, cardiology, nephrologists and others) from each participating country. Local national coordinators will select doctors on an address-based random way, which takes into consideration the proportion of the population. Approximately 1200 centres and 4400 medical practitioners will be targeted. Sampling will be based on urban and rural regions, clustered into geographical areas for which primary care doctors are available. The study monitors will train participating doctors regarding study procedures. The protocol specifically excludes any systematic choice of patients. Monitors will also caution doctors to neither change their routine practice behaviours or to selectively invite patients for participation on the step three of the trial, in order to provide a typical picture of their everyday practice and to avoid major selection effects.
There will be various proportions of GP versus the specialists and the various subcategories of specialists in different settings, that is, government clinic, not for profit institutions and private clinics. This information will be captured in the registry with the intention of comparison among physicians and practice setting. However, comparison will be difficult, because different countries have different health care structures. For instance, in some countries physicians are based exclusively in government clinics, while in other countries recruitment will be family practice based. Comparison of physicians' attitudes within countries will therefore be very limited and across countries will need to be carefully addressed.
Instruments and measures
Participating doctors will be required to fill in a specific Data Collection Form (DCF). Each patient will be identified by a unique identification number, which will include country number (use ISO codes), centre number, patient number and patient initials. The DCF will serve to collect information on the nature of the practice setting, physician's attitude and perceptions towards guidelines and programs for hypertension management. In the DCF a series of questions will assess doctors' attitudes towards BP goals based on patient's characteristics (presence or absence of diabetes, cardiac disease, other risk factors, etc.) and grade of hypertension. The doctor will be asked (1) which guidelines he/she is following (WHO/ISH, JNC-7, national), (2) which target he/she believes the guidelines recommend for his/her specific patient, (3) which target he/she is targeting for the same patient and (4) if there is a difference between recommended target and target decided by the doctor, what is the reason to aim for a different target.
The patients' section of the DCF will be used to collect data on a variety of variables including biosocial characteristics, risk factors, target organ damage and associated clinical conditions. Information about current antihypertensive medication will be collected in the structured clinical assessment form. Information on current BP and clinical chemistry as well as the doctor's assessment on BP goals to achieve for each individual patient will also be collected. Systolic and diastolic BP will be measured using sphygmomanometry or automated, validated devices. This program is a naturalistic study in routine care with no monitor carrying out quality assurance and thus it will not be feasible to quantify to what degree doctors complied with the rules. In particular, it is not possible to indicate whether doctors will base their hypertension indication on one or more measurements.
Diagnostic conventions
Hypertension will be classified in accordance with the definition adopted by NHANES, 21 which defines hypertension as measured BPX140/90 mmHg or receiving antihypertensive therapy, irrespective of the doctor's or patient's self-reported diagnosis. Since isolated systolic hypertension tends to be treated less frequently than diastolic hypertension, 15, 22 this issue will be analysed separately using the definition of isolated systolic hypertension as systolic BPX140 mmHg and diastolic BPo90 mmHg.
Statistical analyses
Statistical analysis will be based on all patients enrolled in the registry. Data will be summarised using mean, median, s.d. and range for continuous parameters and counts and percentages for categorical parameters. Exploratory analysis will be performed in order to determine predictive factors, which could explain probabilities to reach target values. Univariate analysis will be carried out for each possible factor. Significant parameters will be included in the multivariate model and selected with a stepwise process. Odds ratios will be provided with their confidence interval. As this is a descriptive registry, no sample size calculation will be applied. For this part of the trial the last visit will be defined as the last observation carried forward. Separate analyses are planned for patients with diabetes, isolated systolic hypertension and for individual countries.
All tests performed will be bilateral with a risk a equal to 5%. Analysis will be performed with the software SAS s , 8.2, SAS Institute, NC, Cary, USA.
Commentary
The RIAT international survey will collect for the first time representative national data on the local treatment guidelines, attitudes and control status of hypertension as well as the presence of associated comorbidities in about 33 000 hypertensive patients in primary care from 17 countries throughout four continents. Despite considerable advances in the pharmacological treatment of hypertension the management of this important risk factor in general care remains insufficient. This survey shall document the enormous burden of the management of hypertensive patients encountered in primary care practices, and highlights the issues relating to the inadequacy of BP control in these patients (Table 3) .
Further analyses of the RIAT data set should provide important insights both into the characteristics and predictors of poor hypertension control in the participating countries and point to other relevant issues related to the diagnosis and management of patients with high CV risk in primary practice.
Inclusion K Failure of physicians to adhere to hypertension guidelines partly accounts for the failure to achieve blood pressure goals in clinical practice. 9, [11] [12] [13] [14] [15] [16] [17] K With increasing economic and demographic development, chronic, non-communicable, lifestyle-related diseases, such as hypertension and diabetes are on the rise in non-Western countries.
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K Physicians' attitudes in the management of hypertension differ among various countries of dissimilar cultural or ethnic background.
11, [14] [15] [16] [17] What this Study adds: K It will enable to ascertain the reasons why physicians fail to achieve blood pressure goals in various countries in South America, Asia, Africa and Eastern Europe. K It will provide information on physicians' attitudes in the management of hypertension in those regions and whether and to what extent they differ among countries of disparate cultural and ethnic background. K It will allow identifying specific issues in the management of hypertension, for which efforts are required to intensify information strategies for improving professional education, training and practice organization aimed at achieving therapeutic goals.
